Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Endotis Pharma

This article was originally published in Start Up

Executive Summary

Endotis Pharma joins the growing ranks of firms focused on glycoscience, or the science of sugars. Endotis' expertise is twofold: in understanding and regulating protein-sugar interactions, and in synthesizing small sugar-based drugs, or "glycodrugs," which can disrupt these interactions.

You may also be interested in...



Glycan Biosciences Inc.

While recent advances have revealed the chemical structures of glycosaminoglycans and their enormous biological importance, cost-effective and scalable synthesis has been a consistent barrier to commercialization. Glycan Biosciences thinks it's solved the problem with its chemistry platform, Glycolink, which uses inexpensive pharmaceutical-grade feedstocks, simplified chemistry, and employs only a few steps. The technology has yielded numerous promising NCEs, including some for respiratory disease, Glycan's primary therapeutic target.

Glycobiology's Second Wave

New technologies to characterize and manipulate carbohydrate chemistries and the glycosylation of proteins are spawning viable business models that address what scientists have long known: the sugar coating of proteins and cells is not decorative.

Market Access After COVID-19: Sector Goodwill Or Hard Crackdown?

The pandemic has brightened pharma’s image, but drug pricing is still high on the political agenda. For US and European politicians, the health crisis has heightened the tension between supporting innovation and controlling rising costs.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC091226

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel